TLIS Key Statistics, Chart & Performance
The current stock price of TLIS is 4.38 USD. In the past month the price decreased by -50.79%. In the past year, price decreased by -27.24%.
TLIS Technical Analysis
TLIS Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to TLIS. While TLIS has a great health rating, there are worries on its profitability.
TLIS Financial Highlights
Over the last trailing twelve months TLIS reported a non-GAAP Earnings per Share(EPS) of -31.43. The EPS increased by 42.72% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -69.35% | ||
| ROE | -100.93% | ||
| Debt/Equity | 0 |
TLIS Forecast & Estimates
6 analysts have analysed TLIS and the average price target is 5.1 USD. This implies a price increase of 16.44% is expected in the next year compared to the current price of 4.38.
For the next year, analysts expect an EPS growth of 27.62% and a revenue growth -100% for TLIS
TLIS Ownership
About TLIS
Company Profile
Talis Biomedical Corp. develops and commercializes innovative products that are designed to enable accurate, reliable, low cost and rapid molecular testing for infectious diseases. The company is headquartered in Chicago, Illinois and currently employs 99 full-time employees. The company went IPO on 2021-02-12. The firm is focused on advancing health equity and outcomes through the delivery of accurate infectious disease testing in the moment of need, at the point of care.
Company Info
TALIS BIOMEDICAL CORP
1375 West Fulton Market, Suite 700
Chicago ILLINOIS 94025 US
CEO: Brian Coe
Employees: 99
Phone: 16504333000
TALIS BIOMEDICAL CORP / TLIS FAQ
Can you describe the business of TALIS BIOMEDICAL CORP?
Talis Biomedical Corp. develops and commercializes innovative products that are designed to enable accurate, reliable, low cost and rapid molecular testing for infectious diseases. The company is headquartered in Chicago, Illinois and currently employs 99 full-time employees. The company went IPO on 2021-02-12. The firm is focused on advancing health equity and outcomes through the delivery of accurate infectious disease testing in the moment of need, at the point of care.
Can you provide the latest stock price for TALIS BIOMEDICAL CORP?
The current stock price of TLIS is 4.38 USD. The price increased by 5.29% in the last trading session.
Does TLIS stock pay dividends?
TLIS does not pay a dividend.
How is the ChartMill rating for TALIS BIOMEDICAL CORP?
TLIS has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
On which exchange is TLIS stock listed?
TLIS stock is listed on the Nasdaq exchange.
What is the market capitalization of TLIS stock?
TALIS BIOMEDICAL CORP (TLIS) has a market capitalization of 7.97M USD. This makes TLIS a Nano Cap stock.